CSOP SK Hynix Daily (2x) Leveraged Product(07709.HK) Rose 18.80% to 97.200 HKD
Newtimespace News, as of 14:16 on May 21, CSOP SK Hynix Daily (2x) Leveraged Product(07709.HK) was quoted at HKD 97.200, up 18.80%. The ETF opened at HKD 93.620, with a high of HKD 98.880 and a low of HKD 92.700. The latest Net Asset Value (NAV) per unit is HKD 79.485, with a premium rate of 2.94%. The asset size is approximately HKD 48.523 billion.
CSOP SK Hynix Daily (2x) Leveraged Product(07709.HK) is a leveraged and inverse product issued by CSOP Asset Management Limited. It aims to provide, before fees and expenses, investment returns that correspond to twice (2x) the daily performance of the ordinary shares of SK hynix Inc. of South Korea, primarily through the use of financial derivative instruments such as swap contracts. This product features a daily reset mechanism and is a high-risk investment vehicle with significant price volatility. It is typically suitable for experienced and aggressive investors with a clear view on short-term market trends for short-term trading.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Daily Report on Hong Kong-Listed LLM Concept Stocks (July 10, 2026)
- KNOWLEDGE ATLAS(02513.HK) closed 19.29% lower, closing at HKD 1640
- TAN CHONG INT'L (00693.HK): Expected Unrealised Investment Loss of HK$512 Million for First Half Due to Share Price Movements of Listed Investments
- SBP GROUP (01177.HK): NDA Accepted for Category 1 Innovative Drug IDH1 Inhibitor TQB3454 for Advanced Biliary Tract Cancer
- Pizu Group(09893.HK): Change of Independent Non-executive Director, Appointment of Wei Lai